Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.
2.

Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam.

Reese MJ, Bowers GD, Humphreys JE, Gould EP, Ford SL, Webster LO, Polli JW.

Xenobiotica. 2016;46(5):445-56. doi: 10.3109/00498254.2015.1081993. Epub 2015 Sep 4.

PMID:
26340566
3.

Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans.

Bowers GD, Culp A, Reese MJ, Tabolt G, Moss L, Piscitelli S, Huynh P, Wagner D, Ford SL, Gould EP, Pan R, Lou Y, Margolis DA, Spreen WR.

Xenobiotica. 2016;46(2):147-62. doi: 10.3109/00498254.2015.1060372. Epub 2015 Jul 1.

PMID:
26134155
4.

Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBaseā„¢.

Suzuki A, Yuen NA, Ilic K, Miller RT, Reese MJ, Brown HR, Ambroso JI, Falls JG, Hunt CM.

Regul Toxicol Pharmacol. 2015 Aug;72(3):481-90. doi: 10.1016/j.yrtph.2015.05.004. Epub 2015 May 16. Erratum in: Regul Toxicol Pharmacol. 2015 Oct;73(1):348.

5.

Ependymal and periventricular magnetic resonance imaging changes in four dogs with central nervous system blastomycosis.

Bentley RT, Reese MJ, Heng HG, Lin TL, Shimonohara N, Fauber A.

Vet Radiol Ultrasound. 2013 Sep-Oct;54(5):489-96. doi: 10.1111/vru.12049. Epub 2013 May 13.

PMID:
23663013
6.

Disposition and metabolism of GSK2251052 in humans: a novel boron-containing antibiotic.

Bowers GD, Tenero D, Patel P, Huynh P, Sigafoos J, O'Mara K, Young GC, Dumont E, Cunningham E, Kurtinecz M, Stump P, Conde JJ, Chism JP, Reese MJ, Yueh YL, Tomayko JF.

Drug Metab Dispos. 2013 May;41(5):1070-81. doi: 10.1124/dmd.112.050153. Epub 2013 Feb 25.

PMID:
23439661
7.

In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.

Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, Webster LO, Harmon KA, Clarke JD, Polli JW.

Drug Metab Dispos. 2013 Feb;41(2):353-61. doi: 10.1124/dmd.112.048918. Epub 2012 Nov 6.

PMID:
23132334
8.

Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.

Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.

Chem Res Toxicol. 2012 Oct 15;25(10):2067-82. doi: 10.1021/tx300075j. Epub 2012 Sep 19.

PMID:
22931300
9.

Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies.

Sigafoos JF, Bowers GD, Castellino S, Culp AG, Wagner DS, Reese MJ, Humphreys JE, Hussey EK, O'Connor Semmes RL, Kapur A, Tao W, Dobbins RL, Polli JW.

Drug Metab Dispos. 2012 Nov;40(11):2090-101. doi: 10.1124/dmd.112.047258. Epub 2012 Jul 30.

PMID:
22851617
10.

Effects of maternally-derived antibodies on serologic responses to vaccination in kittens.

Digangi BA, Levy JK, Griffin B, Reese MJ, Dingman PA, Tucker SJ, Dubovi EJ.

J Feline Med Surg. 2012 Feb;14(2):118-23. doi: 10.1177/1098612X11432239.

PMID:
22314087
11.

Effects of anesthesia and surgery on serologic responses to vaccination in kittens.

Reese MJ, Patterson EV, Tucker SJ, Dubovi EJ, Davis RD, Crawford PC, Levy JK.

J Am Vet Med Assoc. 2008 Jul 1;233(1):116-21. doi: 10.2460/javma.233.1.116.

PMID:
18593319
12.

An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction.

Reese MJ, Wurm RM, Muir KT, Generaux GT, St John-Williams L, McConn DJ.

Drug Metab Dispos. 2008 Jul;36(7):1198-201. doi: 10.1124/dmd.107.020198. Epub 2008 Apr 17.

PMID:
18420781
13.

Effect of vaccination on parvovirus antigen testing in kittens.

Patterson EV, Reese MJ, Tucker SJ, Dubovi EJ, Crawford PC, Levy JK.

J Am Vet Med Assoc. 2007 Feb 1;230(3):359-63.

PMID:
17269866
14.

Neuromuscular blocking activity and therapeutic potential of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeys.

Boros EE, Samano V, Ray JA, Thompson JB, Jung DK, Kaldor I, Koble CS, Martin MT, Styles VL, Mook RA Jr, Feldman PL, Savarese JJ, Belmont MR, Bigham EC, Boswell GE, Hashim MA, Patel SS, Wisowaty JC, Bowers GD, Moseley CL, Walsh JS, Reese MJ, Rutkowske RD, Sefler AM, Spitzer TD.

J Med Chem. 2003 Jun 5;46(12):2502-15.

PMID:
12773054
15.

The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes.

Walsh JS, Reese MJ, Thurmond LM.

Chem Biol Interact. 2002 Nov 10;142(1-2):135-54.

PMID:
12399160
16.

A kinetic enzyme immunoassay for the quantitation of antibodies to a humanized monoclonal antibody in human serum.

Thurmond LM, Reese MJ, Donaldson RJ, Orban BS.

J Pharm Biomed Anal. 1998 Apr;16(8):1317-28.

PMID:
9777606
17.

Differential neutralizing activity of human antibodies in interferon antiviral and natural killer cell bioassays.

Thurmond LM, Reese MJ.

J Interferon Cytokine Res. 1997 Oct;17(10):619-23.

PMID:
9355963
18.

Immunochemical characterization of human antibodies to lymphoblastoid interferon.

Thurmond LM, Reese MJ.

Clin Exp Immunol. 1991 Dec;86(3):514-9.

19.

Human dermal fibroblasts synthesize laminin.

Woodley DT, Stanley JR, Reese MJ, O'Keefe EJ.

J Invest Dermatol. 1988 May;90(5):679-83.

20.

Epidermolysis bullosa acquisita antigen is the globular carboxyl terminus of type VII procollagen.

Woodley DT, Burgeson RE, Lunstrum G, Bruckner-Tuderman L, Reese MJ, Briggaman RA.

J Clin Invest. 1988 Mar;81(3):683-7.

21.

Specific affinity between fibronectin and the epidermolysis bullosa acquisita antigen.

Woodley DT, O'Keefe EJ, McDonald JA, Reese MJ, Briggaman RA, Gammon WR.

J Clin Invest. 1987 Jun;79(6):1826-30.

22.

Localization of the alpha 3 (V) chain of type V collagen in human skin.

Woodley DT, Scheidt VJ, Reese MJ, Paller AS, Manning TO, Yoshiike T, Briggaman RA.

J Invest Dermatol. 1987 Mar;88(3):246-52.

23.

Neonatal foreskin substrate has limitations for the immunofluorescent screening of monoclonal antibodies.

Woodley DT, Ernst T, Reese MJ, Ogden NM, Gammon WR, Briggaman RA, Falk RJ.

J Invest Dermatol. 1987 Feb;88(2):167-71.

24.

Epidermolysis bullosa acquisita antigen, a major cutaneous basement membrane component, is synthesized by human dermal fibroblasts and other cutaneous tissues.

Woodley DT, Briggaman RA, Gammon WR, Falk RJ, Reese MJ, Tomsick RS, O'Keefe EJ.

J Invest Dermatol. 1986 Aug;87(2):227-31.

25.

Epidermolysis bullosa acquisita antigen, a new major component of cutaneous basement membrane, is a glycoprotein with collagenous domains.

Woodley DT, O'Keefe EJ, Reese MJ, Mechanic GL, Briggaman RA, Gammon WR.

J Invest Dermatol. 1986 Jun;86(6):668-72.

Supplemental Content

Loading ...
Support Center